7th Annual Hematology and Medical Oncology Board Review:
CONTEMPORARY PRACTICE

March 8-11, 2019
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
New York
The target audience for this course is medical oncology professionals, as well as hematologic oncology, genitourinary, soft tissue and skin, and central nervous system oncology, as well as hematologic oncology.

Target Audience
The target audience for this course is medical oncology professionals, including physicians, nurses, pharmacists, fellows and residents.

Educational Objectives
- Learn state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers
- Learn state-of-the-science in diagnosis, staging, and therapeutic management of hematologic cancers
- Understand recent treatment advances in solid tumor and hematologic oncology and their impact on modern clinical practice

MSK Course Directors
David H. Ilson, MD, PhD
Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College

Paul A. Hamlin, MD
Medical Director, David H. Koch Center for Cancer Care
Associate Attending, Lymphoma Service
Division of Hematologic Malignancies
Department of Medicine
Associate Professor of Medicine, Weill Cornell Medical College

MSK Course Faculty
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Carol Aghajanian, MD
Attending Physician, Chief, Gynecologic Medical Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Dean F. Bajorin, MD, FACP
Attending Physician, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Renier J. Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Associate Attending, Lymphoma Service
Department of Medicine

Andrea Cernek, MD
Assistant Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Paul B. Chapman, MD
Attending Physician, Melanoma and Immunotherapeutics service
Division of Solid Tumor Oncology
Department of Medicine

Hiram S. Cody III, MD, FACS
Attending Surgeon
Breast Service
Department of Surgery
Professor of Surgery, Weill Cornell Medical College

Chau T. Dang, MD
Chief, West Hamilton Medical Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Mark A. Dickson, MD
Associate Attending Physician, Sarcoma Medical Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Darren R. Feldman, MD
Assistant Attending Physician, Gynecologic Oncology Service
Division of Gynecologic Oncology
Department of Medicine

Rachel N. Grisham, MD
Assistant Attending Physician, Gynecologic Medical Oncology Service
Division of Gynecologic Oncology
Department of Medicine

Minal M. Gounder, MD
Assistant Attending Physician, Sarcoma Medical Oncology Service
Early Drug Development Service
Division of Solid Tumor Oncology
Department of Medicine

Christian Grommes, MD
Assistant Attending Physician
Brain Tumor Service
Department of Neurology

Komal Jhaveri, MD, FACP
Attending
Breast Medicine Service and Early Drug Development Service
Department of Medicine

Philip Kantoff, MD
Chaimer, Department of Medicine
Professor of Medicine, Weill Cornell Medical College

C. Ola Landgren, MD, PhD
Chief, Hematology Service
Division of Hematologic Oncology
Department of Medicine

Bob T. Li, MD, MPH
Assistant Attending Physician, Thoracic Oncology Service
Developmental Therapeutics
Division of Solid Tumor Oncology
Department of Medicine

Simon Mantha, MD, MPH
Assistant Attending Physician, Hematology Service
Division of Hematologic Oncology
Department of Medicine

Michael J. Mauro, MD
Attending Physician
Leukemia Service
Division of Hematologic Oncology
Department of Medicine

Beryl McCormick, MD, FACP
Chief, External Beam Radiotherapy Service
Department of Radiation Oncology
Professor of Radiation Oncology, Weill Cornell Medical College

Jodi Mones, MD
Associate Attending, Hematology Service
Division of Hematologic Oncology
Department of Medicine

Alison J. Moskowitz, MD
Clinical Director, Lymphoma Inpatient Unit
Assistant Attending, Lymphoma Service
Department of Medicine

Robert J. Motzer, MD
Attending Physician, Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Eileen M. O'Reilly, MD
Associate Director for Clinical Research, David H. Rubenstein Center for Pancreatic Cancer
Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Miguel-Angel Perales, MD
Chief, Adult Bone Marrow Transplantation Fellowship Program
Department of Medicine

Gregory J. Riely, MD, PhD
Vice Chair, Clinical Research
Associate Attending, Thoracic Oncology Service
Department of Medicine

Leonard B. Saltz, MD
Executive Director for Clinical Value and Sustainability
Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Susan Seo, MD
Attending Physician
Infectious Disease service
Division of General Medicine
Department of Medicine

Zsofia K. Stadler, MD
Chief, Clinical Trials Unit
Division of Gastrointestinal Oncology Services
Associate Attending Physician, Clinical Genetics and Gastrointestinal Oncology Services
Division of Solid Tumor Oncology
Department of Medicine

Martin S. Tallman, MD
Chief, Lymphoma Service
Division of Hematologic Oncology
Department of Medicine

Anna M. Varghese, MD
Assistant Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Marjorie G. Zauderer, MD
Co-Director, Adult Bone Marrow Transplant Fellowship Program
Assistant Attending Physician, Thoracic Oncology Service
Division of Solid Tumor Oncology
Department of Medicine

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Lymphoma Service
Division of Hematologic Oncology
Department of Medicine
Day 1 | Friday, March 8

8:30 AM  Breakfast and Registration

Solid Tumor Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>Colon Cancer</td>
<td>Leonard B. Saltz, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Melanoma</td>
<td>Paul B. Chapman, MD</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Prostate Cancer</td>
<td>Philip Kantoff, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Kidney Cancer</td>
<td>Robert J. Motzer, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Mesothelioma</td>
<td>Marjorie G. Zauderer, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Urothelial Cancer</td>
<td>Dean F. Bajorin, MD, FACP</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Testis Cancer</td>
<td>Darren R. Feldman, MD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Uterine/Cervix/Other GYN Cancers</td>
<td>Carol Aghajanian, MD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Ovarian Cancer</td>
<td>Rachel N. Grisham, MD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Breast Cancer/Surgery</td>
<td>Hiram S. Cody III, MD, FACS</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Breast Cancer/Radiation Therapy</td>
<td>Beryl McCormick, MD, FACR</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Esophageal and Gastric Cancer</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Day 2 | Saturday, March 9

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>7:00 AM</td>
<td>Small Cell Lung Cancer</td>
<td>Bob T. Li, MD, MPH</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Breast Cancer/Advanced Disease</td>
<td>Komal Jhaeri, MD, FACP</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Breast Cancer/Adjuvant Therapy</td>
<td>Chau T. Dang, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Breast Cancer/Hormonal Therapy</td>
<td>Devika Gajria, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Carcinoma of Unknown Primary</td>
<td>Anna M. Varghese, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Hepatocellular Cancer and Cholangiocarcinoma</td>
<td>Ghassan K. Abou-Alfa, MD, MBA</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Pancreatic and Neuroendocrine Cancer</td>
<td>Eileen M. O’Reilly, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Non Small Cell Lung Cancer</td>
<td>Gregory J. Riely, MD, PhD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Head and Neck, Thyroid Cancer</td>
<td>David G. Pfister, MD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Anal/Rectal Cancer</td>
<td>Andrea Cercek, MD</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

Day 3 | Sunday, March 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Pharmacology I</td>
<td>Mrinal M. Gounder, MD</td>
</tr>
<tr>
<td>8:15 AM</td>
<td>Pharmacology II</td>
<td>Mrinal M. Gounder, MD</td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Thrombocytopenia, ITP and Beyond</td>
<td>Gerald Soff, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Low Grade NHL/CLL</td>
<td>Andrew D. Zelenetz, MD, PhD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>DLBCL/MCL/BL</td>
<td>Paul Hamlin, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>HL/T Cell</td>
<td>Alison J. Moskowitz, MD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Auto/Allo</td>
<td>Miguel-Angel Perales, MD</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>AML/ALL</td>
<td>Martin S. Tallman, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>MDS/MPN</td>
<td>Michael J. Mauro, MD</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Myeloma/Amyloid</td>
<td>C. Ola Landgren, MD, PhD</td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Day 4 | Monday, March 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 AM</td>
<td>Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>CART cells</td>
<td>Renier J. Brentjens, MD, PhD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>The Role of the Direct Oral Anticoagulants in Practice</td>
<td>Simon Mantha, MD, MPH</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Approach to The Bleeding Patient</td>
<td>TBA</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Sickle Cell Disease, Thalassemia</td>
<td>Jodi Mones, MD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

Live Simulcast Available for MSK Cancer Alliance Members.
Visit mskcc.org/HemOncBoardReview for more information.
REGISTRATION FEES

<table>
<thead>
<tr>
<th>Physician Group</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs and DOs)</td>
<td>$1500</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses and Other Healthcare Providers</td>
<td>$975</td>
</tr>
<tr>
<td>Industry Professionals*</td>
<td>$2,525</td>
</tr>
</tbody>
</table>

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Register online: mskcc.org/HemOncBoardReview

Course registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations.

- **MSK CME offers a 30% discounted rate for MSK Alumni, MSK Cancer Alliance* and Cancer Care Partners.** If you are a member of one of these groups, please contact cme@mskcc.org for more information.

  *We are also offering a live simulcast option for MSK Cancer Alliance members. Please visit the course website for more information.

- **MSK employee registration is complimentary.** However, you must complete course registration in order to attend this course.

Accreditation
Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement
Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **30.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **30.75 Medical Knowledge MOC points** in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Conference Location & Accommodations
Zuckerman Research Center
417 East 68th Street
New York, NY 10065

MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the vicinity of MSK with discounted rates, please visit: mskcc.org/cme.

Contact
Memorial Sloan Kettering Cancer Center
Office of Continuing Medical Education
mskcc.org/cme
cme@mskcc.org